In contrast, in primary BC cohorts such as TCGA and GSE199135, where patients had not received NAC, CIBERSORT-derived immune cell fractions showed minimal differences between ER-high and ER-low tumors, reflecting baseline tumor immunity rather than treatment-induced modulation (Figure S1). This evidence concerns the gene ESR1 and neoplasm.